Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan M Kelley

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Frontiers in Psychology|April 20, 2016
Corticostriatal Field Potentials Are Modulated at Delta and Theta Frequencies during Interval-Timing Task in RodentsEric B Emmons, Rafael N Ruggiero, Ryan M Kelley, et al.
Parkinsonism & Related Disorders|March 16, 2019
Effect of deep brain stimulation on vocal motor control mechanisms in Parkinson's diseaseRoozbeh Behroozmand, Karim Johari, Ryan M Kelley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 3, 2005
Conserved patterns of protein interaction in multiple speciesRoded Sharan, Silpa Suthram, Ryan M Kelley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2010
Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humansAmin Kamel, R Scott Obach, Kevin Colizza, et al.
Frontiers in Human Neuroscience|March 6, 2023
Human subthalamic nucleus neurons differentially encode speech and limb movementKarim Johari, Ryan M Kelley, Kris Tjaden, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Frontiers in Psychology|April 20, 2016
Corticostriatal Field Potentials Are Modulated at Delta and Theta Frequencies during Interval-Timing Task in RodentsEric B Emmons, Rafael N Ruggiero, Ryan M Kelley, et al.
Parkinsonism & Related Disorders|March 16, 2019
Effect of deep brain stimulation on vocal motor control mechanisms in Parkinson's diseaseRoozbeh Behroozmand, Karim Johari, Ryan M Kelley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 3, 2005
Conserved patterns of protein interaction in multiple speciesRoded Sharan, Silpa Suthram, Ryan M Kelley, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 30, 2010
Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humansAmin Kamel, R Scott Obach, Kevin Colizza, et al.
Frontiers in Human Neuroscience|March 6, 2023
Human subthalamic nucleus neurons differentially encode speech and limb movementKarim Johari, Ryan M Kelley, Kris Tjaden, et al.
Chemical Research in Toxicology|May 29, 2010
Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosisAmit S Kalgutkar, David A Griffith, Tim Ryder, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2009
Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonistsMary T Didiuk, David A Griffith, John W Benbow, et al.
Pageof 1